On this page
Kallmann syndrome (X-linked)
This syndrome primarily affects males and results in a failure to undergo typical puberty, alongside an inability to smell. Early diagnosis is important for timely hormone replacement therapy and improved quality of life.
Overview
Kallmann syndrome (X-linked) is a rare genetic disorder that impacts hormonal development and the sense of smell. Individuals with this condition experience hypogonadotropic hypogonadism, which means their body doesn't produce enough of the hormones needed for sexual development and reproduction. This leads to absent or incomplete puberty. A hallmark feature of Kallmann syndrome is also an impaired (hyposmia) or absent (anosmia) sense of smell [PMID:28795552].
The condition is often identified when a person, typically male, does not start puberty at the expected age. Although primarily affecting males, females can also be carriers or, in rare cases, show milder symptoms. While the hormonal and olfactory issues are central, other symptoms can sometimes be associated with the syndrome.
Symptoms & clinical features
The primary symptoms of Kallmann syndrome (X-linked) are a lack of puberty and an impaired sense of smell. Males with this condition will typically not experience growth of the testes, deepening of the voice, or development of facial and pubic hair. Females who are affected may experience absent or very sparse menstrual periods, along with underdeveloped breasts [PMID:28795552].
Regarding the sense of smell, individuals may either have a complete inability to smell (anosmia) or a significantly reduced ability (hyposmia). This can sometimes go unnoticed for many years, but specific tests can confirm the extent of olfactory impairment. Other features that may sometimes be associated include cleft lip or palate, kidney problems, specific neurological issues, and hearing loss, although these are less common.
Video: Genetics 101
Affected organs
The main organs affected in Kallmann syndrome (X-linked) are those involved in hormone production and the sense of smell. The hypothalamus and pituitary gland in the brain, which normally produce and release hormones critical for puberty, do not function correctly. This leads to the testes in males and ovaries in females not receiving the signals needed to produce sex hormones, thus affecting reproductive development.
The olfactory bulbs and tracts, which are parts of the brain responsible for processing smells, are typically underdeveloped or absent. This anatomical abnormality directly causes the impaired sense of smell. In some instances, other organs such as the kidneys or parts of the brain controlling balance and movement can also be affected, leading to a broader range of symptoms.
Risks & severity
Kallmann syndrome (X-linked) primarily affects males, with an estimated prevalence of about 1 in 30,000 males. The severity of both the hormonal deficiency and the impairment of smell can vary between individuals, even within the same family. Without treatment, males will experience infertility and may have reduced bone density due to low sex hormone levels [PMID:28795552].
The condition generally does not affect lifespan, but the lack of sex hormones can lead to long-term health issues if left untreated. These can include a higher risk of osteoporosis (weak bones) and psychological impacts related to delayed or absent puberty. Early diagnosis and appropriate hormone replacement therapy are key to managing these risks.
Genetic causes
Kallmann syndrome (X-linked) is caused by pathogenic variants in the ANOS1 gene. This gene provides instructions for making a protein called anosmin 1. This protein plays a crucial role during early foetal development, particularly in the migration of specific nerve cells.
Anosmin 1 is essential for guiding neurons that produce gonadotrophin-releasing hormone (GnRH) from their origin in the nose to their correct location in the brain. GnRH is a key hormone that signals the pituitary gland to produce other hormones necessary for sexual development. Pathogenic changes in ANOS1 disrupt the normal function of anosmin 1, preventing these GnRH-producing neurons and olfactory neurons from reaching their proper destinations, leading to the characteristic features of the syndrome [PMID:33610996].
- ANOS1 anosmin 1
Inheritance pattern
Kallmann syndrome (X-linked) follows an X-linked recessive inheritance pattern. This means that the ANOS1 gene is located on the X chromosome. Males have one X and one Y chromosome, so if their X chromosome carries a pathogenic variant in ANOS1, they will develop the condition.
Females have two X chromosomes. If a female has a pathogenic variant on one X chromosome, she is typically a carrier and usually does not show significant symptoms because her other normal X chromosome can compensate. However, some female carriers may experience milder symptoms, such as a reduced sense of smell or delayed puberty. Carrier females have a 50% chance of passing the pathogenic variant to each child. Sons who inherit the variant will be affected, while daughters who inherit it will be carriers.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
Diagnosis & testing
Diagnosis of Kallmann syndrome (X-linked) typically involves a combination of clinical evaluation, hormone tests, and an assessment of the sense of smell. When puberty fails to start by the expected age, or when an impaired sense of smell is noted alongside hormonal deficiencies, a specialist will investigate further. Blood tests will measure levels of sex hormones (like testosterone or oestrogen) and the pituitary hormones that stimulate their production (LH and FSH), which will be unusually low.
Genetic testing, specifically looking for pathogenic variants in the ANOS1 gene, can confirm a diagnosis of Kallmann syndrome (X-linked). This testing is generally arranged through a clinical genetics service following referral from an endocrinologist or paediatrician. In the UK, genetic testing for this condition may be performed under an NHS Genomic Medicine Service 'R-code', such as R146 Hypogonadotrophic hypogonadism, to identify the specific genetic cause.
Management & lifestyle
Management of Kallmann syndrome (X-linked) primarily focuses on hormone replacement therapy. For males, this typically involves testosterone replacement, which induces puberty, supports the development of secondary sexual characteristics, and helps maintain bone density. For females, oestrogen and progesterone replacement therapy is used to induce puberty and support menstrual cycles. These therapies usually continue long-term [PMID:33610996].
If fertility is desired, alternative hormone treatments involving gonadotropins can be considered, which may stimulate sperm production in males or egg development in females. Regular monitoring by an endocrinologist is essential to adjust hormone dosages and manage any associated health concerns. Genetic counselling is also important for affected individuals and their families to understand the inheritance pattern and reproductive options.
UK care pathway
In the UK, individuals suspected of having Kallmann syndrome (X-linked) typically enter the NHS Genomic Medicine Service pathway. Initial assessment and referral usually come from a GP to a specialist, such as a paediatrician or endocrinologist, particularly if delayed puberty is a concern. If a genetic condition is suspected, referral to a regional clinical genetics service will be made.
Clinical genetics teams, including genetic counsellors, provide comprehensive information about the condition, coordinate genetic testing (often using an R-code from the NHS National Genomic Test Directory, such as R146), and discuss implications for family members. Management and ongoing care are usually coordinated by an endocrinology team, with support from other specialists as needed.
Frequently asked questions
Will my child be able to have children if they have Kallmann syndrome (X-linked)?
Fertility can be a concern for individuals with Kallmann syndrome (X-linked). While standard hormone replacement therapy helps with puberty and general health, it does not always restore fertility. However, specific fertility treatments involving gonadotropin hormones can sometimes stimulate sperm production in males or ovulation in females, potentially enabling biological parenthood. It's best to discuss options with an endocrinologist and fertility specialist.
How is Kallmann syndrome (X-linked) treated?
The main treatment for Kallmann syndrome (X-linked) is lifelong hormone replacement therapy. For males, this means testosterone, and for females, a combination of oestrogen and progesterone. This therapy helps to induce puberty, develop secondary sexual characteristics, and maintain bone health. Treatment decisions are made by an endocrinologist.
Can females be affected by Kallmann syndrome (X-linked)?
Kallmann syndrome (X-linked) primarily affects males, but females can be carriers of the pathogenic ANOS1 variant. While female carriers often have no symptoms, some may experience milder features such as a reduced sense of smell or delayed puberty. Genetic counselling can provide more personalised information for female carriers and their families.
How will I know if my child has a reduced sense of smell?
A reduced or absent sense of smell (hyposmia or anosmia) can be difficult to notice, especially in younger children, as they may not realise they are different. If Kallmann syndrome is suspected due to delayed puberty, a formal smell test (olfactory test) can be performed by a specialist. This test can objectively measure their ability to detect and identify different odours.
Is Kallmann syndrome (X-linked) always inherited from a parent?
Kallmann syndrome (X-linked) caused by ANOS1 variants is typically inherited from a mother who is a carrier. However, sometimes a new (de novo) pathogenic variant can occur in the ANOS1 gene in the affected individual, meaning neither parent carries the variant. Genetic testing of both parents can help determine if the variant was inherited or de novo.